Biogen/Eisai's Popular Alzheimer's Drug Leqembi Is Seeing Slow Adoption - Here's Why
Nine months after the U.S. launch of Eisai Limited ESALY and Biogen Inc’s BIIB Leqembi, the first drug shown to slow Alzheimer’s progression, adoption faces hurdles due to skepticism among some doctors. Initially hopeful, Alzheimer’s experts anticipated …